Preview

Рецепт

Расширенный поиск

Клинико-фармакологическая характеристика антикоагулянтов

Полный текст:

Аннотация

Артериальные и венозные тромбозы остаются ведущими причинами заболеваемости и смертности. Тромбоз артерий - основная причина инфаркта миокарда, ишемического инсульта и критической ишемии нижних конечностей. Тромбоз глубоких вен приводит к развитию тромбоэмболии легочной артерии. Венозные тромбы состоят преимущественно из тромбина и эритроцитов и содержат относительно небольшое количество тромбоцитов. Соответственно, методом выбора в их лечении и профилактике являются антикоагулянты. Антикоагулянты - это лекарственные средства, препятствующие тромбообразованию за счет воздействия на плазменные факторы свертывания крови (нефракционированный и низкомолекулярные гепарины, варфарин и другие антагонисты витамина К, витамин-К-независимые антикоагулянты). Цели антикоагулянтной терапии включают профилактику распространения тромба в острую фазу и предупреждение ранних и поздних рецидивов венозного тромбоза. В статье представлена клинико-фармакологическая характеристика антикоагулянтов для парентерального и перорального применения. Особое внимание уделено безопасности применения и предупреждению нежелательных эффектов антикоагулянтов в клинической практике.

Об авторах

Л. Н. Гавриленко
Белорусский государственный медицинский университет
Беларусь


И. Н. Кожанова
Белорусский государственный медицинский университет
Беларусь


И. С. Романова
Белорусский государственный медицинский университет
Беларусь


Список литературы

1. Piccini J.P., Patel M.R., Mahaffey K.W. et al. (2008) Rivaroxaban, an oral direct factor Xa inhibitor. Expert Opin Investig Drugs, vol. 17, pp. 925-37.

2. InstruktsiyapomeditsinskomuprimeneniyulekarstvennogosredstvaGeparin[Summaryofproductcharacteristics of medicine Heparine]. Available at: http://www.rceth.by/NDfiles/instr/4316_2000_05_10_15_s.pdf (accessed 25 February 2018)

3. Instruktsiya (informatsiya dlya spetsialistov) po meditsinskomu primeneniyu lekarstvennogo sredstva Varfarin [Summary of product characteristics (for specialists) of medicine Warfarin]. Available at: http://www.rceth. by/NDfiles/instr/16_12_1940_s.pdf (accessed 25 February 2018)

4. Vahanian A., Alfieri O., Andreotti F., et al. (2012) Joint Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology (ESC), European Association for CardioThoracic Surgery (EACTS), Guidelines on the management of valvular heart disease. Eur Heart J, vol. 33, рр. 2451-2496.

5. Camm A.J., Lip G.Y., De Caterina R., Savelieva I. et al. (2012) ESC Committee for Practice Guidelines (CPG). 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. European Heart Journal, vol. 33, pp. 2719-2747.

6. January C.T., Wann L.S., Alpert J.S., et al. (2014) AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. Circulation, vol. 130 (23), pp. 2071-104.

7. Steinberg B.A., Holmes D.N., Ezekowitz M.D. et al. (2013) Rate versus rhythm control for management of atrial fibrillation in clinical practice: results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry. Am Heart J., vol. 165 (4), pp. 622-9.

8. Dezee K., Shimeall W., Douglas K. et al. (2006) Treatment of excessive anticoagulation with phytonadione (vitamin K): a meta-analysis. Arch. Intern. Med., vol. 166, pp. 391-7.

9. Dentali F., Ageno W., Crowther M. (2006) Treatment of coumarin-associated coagulopathy: a systematic review and proposed treatment algorithms. J. Thromb. Haemost., vol. 4, pp. 1853-63.

10. Barillari G., Pasca S., Barillar A. (2012) Emergency reversal of anticoagulation: from theory to real use of prothrombin complex concentrates. A retrospective Italian experience. Blood Transfus., vol. 10, pp. 87-94.

11. Aguilar M., Hart R. et al. (2007) Treatment of Warfarin-Associated Intracerebral Hemorrhage: Literature review and expert Opinion. Mayo Clin. Proc., vol. 82, pp. 182-92.

12. Colomina M., Diez Lobo A., Garutti I. et al. (2012) Perioperative use of prothrombin complex concentrates.

13. Minerva Anestesiol., vol. 78, pp. 358-68.

14. Bruce D., Nokes T. (2008) Prothrombin complex concentrate in severe bleeding: experience in a large tertiary hospital. Crit. Care, vol. 12, pp. 1-9.

15. Mazur-Bialy A.I., Zdebska K., Wypasek E., Undas A. (2013) Repeated bleeding complications during therapy with vitamin K antagonists in a patient with the VKORC1*2A and the CYP2C9*3/*3 alleles: genetic testing to support switching to new oral anticoagulants. Thromb Res., vol. 131 (3), pp. 279-80.

16. Xarelto®. Available at: https://www.rlsnet.ru/tn_index_id_43277.htm (accessed 25 February 2018)

17. Instruktsiya po meditsinskomu primeneniyu preparata Pradaksa [Summary of product characteristics of medicine Pradaxa]. Available at: http://www.rceth.by/NDfiles/instr/8992_09_10_14_15_16_17_i.pdf (accessed 25 February 2018)

18. Budnitz D.S., Lovegrove M.C., Shehab N., Richards C.L. (2011) Emergency hospitalizations for adverse drug events in older Americans. N Eng J Med., vol. 365, pp. 200-2012.

19. Ruff C.T., Giugliano R.P., Braunwald E. et al. (2014) Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lance, vol. 383 (9921), pp. 955-962.

20. Van der Hulle T., Kooiman J., Den Exter P.L. et al. (2014) Effectiveness and safety of novel oral anticoagulants as compared with vitamin K antagonists in the treatment of acute symptomatic venous thromboembolism: a systematic review and meta-analysis. J Thromb Haemost., vol. 12 (3), pp. 320-328.

21. Kaatz S., Kouides P.A., Garcia D.A. et al. (2012) Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors. Am J Hematol., vol. 87, pp. 141-145.

22. Miesbach W., Seifried E. (2012) New direct oral anticoagulants-current therapeutic options and treatment recommendations for bleeding complications. Thromb Haemost., vol. 108, pp. 625-632.

23. Levy J.H., Ageno W., Chan N.C., Crowther M. (2016) When and how to use antidotes for the reversal of direct oral anticoagulants: guidance from the SSC of the ISTH. J Thromb. Haemost., vol. 14, pp. 623-627.

24. Glund S., Stangier J., Schmohl M. et al. (2015) Safety, tolerability, and efficacy of idarucizumab for the reversal of the anticoagulant effect of dabigatran in healthy male volunteers: a randomized, placebo-controlled, double-blind phase 1 trial. Lancet, vol. 386, pp. 680-690.

25. Schiele F., van Ryn J., Canada K. et al. (2014) A specific antidote for dabigatran: functional and structural characterization. Blood, vol. 121 (18), pp. 3554-3562.

26. Becker R.C. (2016) The biochemistry, enzymology and pharmacology of non-vitamin K anticoagulant drug reversal agents and antidotes. J Thromb Thrombolysis, vol. 41, pp. 273-278.

27. Frontera J.A., Lewin III J.J., Rabinstein A.A. et al. (2016) Guideline for Reversal of Antithrombotics in Intracranial Hemorrhage. Neurocrit Care, vol. 24 (1), pp. 6-46.

28. Kakkar Ajay K., Mueller Iris (2013) Risk Profiles and Antithrombotic Treatment of Patients Newly Diagnosed with Atrial Fibrillation at Risk of Stroke: Perspectives from the International, Observational, Prospective GARFIELD Registry. PLOS ONE, vol. 8, Is. 5, p. e63479.

29. Marinigh R., Lip G.Y.H., Fiotti N. (2010) Age as a risk factor for stroke in atrial fibrillation patients: Implications for thromboprophylaxis. J Am Coll Cardiol, vol. 56, pp. 827-837.

30. Zalesak M., Siu K., Francis K., et al. (2013) Higher persistence in newly diagnosed nonvalvular atrial fibrillation patients treated with dabigatran versus warfarin. Circ Cardiovasc Qual Outcomes, vol. 6, pp. 567-74.

31. Kirchhof P., Benussi S., Kotecha D., et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. European Heart Journal. Available at: http://eurheartj.oxfordjournals. org/content/early/2016/08/26/eurheartj.ehw210 (accessed 25 February 2018)

32. Olesen J.B., Lip G.Y., Hansen M.L., et al. (2011) Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study. BMJ, vol. 342, pp. d124.

33. Van de Werf F, Bax J, Betriu A et al., for the ESC Committee for Practice Guidelines (2010) Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J., vol. 31, pp. 2369-429.

34. Gadsbell K. (2017) Increased use of oral anticoagulants in patients with atrial fibrillation: temporal trends from 2005 to 2015 in Denmark. EHJ, vol. 38, pp. 899-906.

35. Xiong Q., Lau Y.C., Senoo K. et al. (2015) Non-vitamin K antagonist oral anticoagulants (NOACs) in patients with concomitant atrial fibrillation and heart failure: a systemic review and meta-analysis of randomized trials. Eur J Heart Fail., vol. 17 (11), pp. 1192-200.

36. Connolly S., Parekh A., Reilly P.A., et al. (2009) Rationale and design of RE-LY: randomized evaluation of long- term anticoagulant therapy, warfarin, compared with dabigatran. Am Heart J., vol. 157 (5), pp. 805-10.

37. ROCKET AF Study Investigators (2010). Rivaroxaban-once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: rationale and design of the ROCKET AF study. Am Heart J., vol. 159 (3), pp. 340-347.

38. (2011) Apixaban for Reduction In STroke and Other ThromboemboLic Events in atrial fibrillation trial. Available at: http://www.anticoagulant-trials.eu/studies-a-z/detail/study/aristotle.html (accessed 25 February 2018)

39. Larsen T.B. et al. (2014) Bleeding events among new starters and switchers to dabigatran compared with warfarin in atrial fibrillation. Am J Med., vol. 127 (7), pp. 650-656.

40. Reichman D.J., Wernecke M.E. (2016) Stroke, bleeding, and mortality risks in elderly medicare beneficiaries treated with dabigatran or rivaroxaban for nonvalvular atrial fibrillation JAMA, vol. 315, pp. 2117-2118.

41. Diener C. (2017) Choosing a particular oral anticoagulant and dose for stroke prevent in individual patients with nonvalvular atrial fibrillation: part 2. EHJ, vol. 38, pp. 860-868.

42. Rekomendatsii ESC po diagnostike i vedeniyu patsientov s ostroi emboliei sistemi legochnoi arterii 2014 [ESC recommendations on diagnostics and maintaining of patients with acute pulmonary embolism 2014]. Available at: http://scardio.ru/content/Guidelines/Recom%20embolia%208_rkj_1.pdf (accessed 25 February 2018).

43. Voigtlaender M., Langer F. (2017) Direct oral anticoagulants for the treatment of cancer-associated venous thromboembolism. What do we know so far? Hamostaseologie, vol. 37 (4), pp. 241-255.

44. Habib G., Lancellotti P., Antunes M.J. et al. (2015) ESC Guidelines for the management of infective endocarditis: The Task Force for the Management of Infective Endocarditis of the European Society of Cardiology (ESC). Endorsed by: European Association for Cardio-Thoracic Surgery (EACTS), the European Association of Nuclear Medicine (EANM). Eur Heart J., vol. 36 (44), pp. 3075-128.

45. Zamorano J.L., Lancellotti P., Rodriguez Muñoz D. et al. (2016) ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J., vol. 37 (36), pp. 2768-2801.


Для цитирования:


Гавриленко Л.Н., Кожанова И.Н., Романова И.С. Клинико-фармакологическая характеристика антикоагулянтов. Рецепт. 2018;(5):572-589.

For citation:


Gavrilenko L..., Kozhanova I..., Romanova I... The clinical and pharmacological characteristics of anticoagulants. Recipe. 2018;(5):572-589. (In Russ.)

Просмотров: 13


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1993-4882 (Print)
ISSN 2414-2263 (Online)